Pfizer reports total sales of $ 15 billion for Covid vaccine and antiviral treatment in the first quarter

MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE

Albert Bourla, CEO of the pharmaceutical company Pfizer, arrives to ring the closing bell of the New York Stock Exchange.

Drew Angerer | Getty Images

Pfizer surpassed its top and bottom lines in the first quarter, driven by strong sales of Covid vaccine and oral antiviral drugs.

The pharmaceutical giant said it sold $ 13.2 billion in its Covid vaccine and $ 1.5 billion in antiviral drug Paxlovid in the first quarter.

Here’s how Pfizer performed compared to the expected Wall Street based on average analyst estimates compiled by Refinitiv:

  • Customized EPS: $ 1.62 per share compared to an expected $ 1.47
  • Revenue: $ 25.66 billion compared to an expected $ 23.86 billion

Pfizer shares were virtually unchanged in pre-sale trading.

The company has reaffirmed its plans for the full year 2022 on $ 32 billion in sales of Covid vaccine and $ 22 billion on Paxlovid.

CNBC Health and Science

Read the latest CNBC global report on the Covida pandemic:

This is a story in development. Check again for updates.

.

MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE

Source

Leave a Comment

error: Content is protected !!